Marshall Wace, LLP Immatics N.V. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $1.24 Million - $1.43 Million	113,036 Added 520.9%	134,736 $1.56 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $128,464 - $276,024	21,700 New	21,700 $250,000
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $276,818 - $1.09 Million	83,631 Added 782.11%	94,324 $944,000
Q2 2022 Aug 15, 2022	BUY	$6.0 - $9.37 $64,158 - $100,193	10,693 New	10,693 $94,000
Q1 2022 May 16, 2022	SELL	$6.64 - $12.85 $19,800 - $38,318	-2,982 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.81 - $14.38 $32,235 - $42,881	2,982 New	2,982 $41,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $566M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.